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Coenzyme QIn this study, we investigated the pathogenicity of a homozygous Asp446Asn mutation in the NDUFS2 gene of
a patient with a mitochondrial respiratory chain complex I deﬁciency. The clinical, biochemical, and genetic
features of the NDUFS2 patient were compared with those of 4 patients with previously identiﬁed NDUFS2
mutations. All 5 patients presented with Leigh syndrome. In addition, 3 out of 5 showed hypertrophic cardio-
myopathy. Complex I amounts in the patient carrying the Asp446Asn mutation were normal, while the com-
plex I activity was strongly reduced, showing that the NDUFS2mutation affects complex I enzymatic function.
By contrast, the 4 other NDUFS2 patients showed both a reduced amount and activity of complex I. The en-
zymatic defect in ﬁbroblasts of the patient carrying the Asp446Asn mutation was rescued by transduction of
wild type NDUFS2. A 3-D model of the catalytic core of complex I showed that the mutated amino acid residue
resides near the coenzyme Q binding pocket. However, the KM of complex I for coenzyme Q analogs of the
Asp446Asn mutated complex I was similar to the KM observed in other complex I defects and in controls.
We propose that the mutation interferes with the reduction of coenzyme Q or with the coupling of coenzyme
Q reduction with the conformational changes involved in proton pumping of complex I.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
NADH:ubiquinone oxidoreductase (complex I, EC 1.6.5.3) cata-
lyzes the ﬁrst step of the electron transport chain in the mitochondri-
al oxidative phosphorylation (OXPHOS) system. It transfers electrons
from NADH to ubiquinone via FMN and iron–sulfur (FeS) clusters. The
transfer of two electrons is coupled to the translocation of four pro-
tons across the mitochondrial inner membrane [1,2]. Human complex
I is a large enzyme complex of approximately 1 MDa that is assem-
bled from 7 mitochondrial-encoded subunits and 38 nuclear-
encoded subunits [3]. In addition, nuclear-encoded assembly factors
such as NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, C8ORF38,nzyme Q; CS, citrate synthase;
ochondrial Disorders, Depart-
rine, and Metabolic Disorders,
x 9101, 6500 HB Nijmegen,
18900.
denburg).
l rights reserved.C20ORF7, ACAD9, and Ecsit are required for the biogenesis of this en-
zyme [4–11]. From a structural point of view, complex I consists of a
peripheral domain protruding into the matrix and a membrane do-
main embedded in the lipid bilayer of the inner mitochondrial mem-
brane. From a functional perspective, it is composed of three different
modules: a NADH-dehydrogenase module, a hydrogenase-like mod-
ule, and a transporter module [12,13]. Isolated mitochondrial com-
plex I deﬁciency is one of the most frequently encountered OXPHOS
disorders [14,15]. Complex I-deﬁcient children are known to present
with a diverse spectrum of clinical manifestation such as progressive
encephalopathy, hypertrophic cardiomyopathy, myopathy, hepato-
pathy and renal tubulopathy. The most common clinical phenotype
is Leigh (-like) syndrome which is an early onset progressive and
often fatal disease [16]. Thus far, disease-causing mutations have
been identiﬁed in all the mitochondrial-encoded subunit and twelve
nuclear-encoded subunit genes. These twelve genes are NDUFA1,
NDUFA2, NDUFA10, NDUFA11, NDUFS1, NDUFS2, NDUFS3, NDUFS4,
NDUFS6, NDUFS7, NDUFS8, NDUFV1, and NDUFV2 [17–29]. In most of
these cases, not only complex I activities were reduced, but also com-
plex I amounts, suggesting that the complex I deﬁciency observed in
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order to broaden our knowledge concerning the clinical and bio-
chemical phenotypes of complex I deﬁciency due to NDUFS2 gene
mutations, we compared a complex I-deﬁcient patient carrying a ho-
mozygous 1336G>A (Asp446Asn) mutation in the NDUFS2 gene that
has not been described in detail before with 4 previously described
patients carrying mutations in NDUFS2.
2. Materials and methods
2.1. Case report
The study described here has been carried out in the Netherlands
in accordance with the applicable rules concerning the review of
research ethics committees and informed consent. Patient 1, a girl,
was the ﬁrst child of healthy, consanguineous Turkish parents. She
was born at 38 weeks of gestation following an uncomplicated second
pregnancy. Her birth weight was 2300 g, birth length 47 cm, APGAR
scores: 8 at 1 min and 9 at 5 min, and umbilical arterial blood pH:
7.19. The ﬁrst pregnancy terminated spontaneously with a fetal loss
at 8 weeks of gestation. Family history revealed that two children of
the mother's sister were severely disabled and both children died
during the ﬁrst year of life. Shortly after birth the mother noticed
that the girl had irregular twitches of the limbs. However, no further
investigations were performed at that time. At the age of 3 months
the girl was admitted to our hospital because of a respiratory infec-
tion. Physical examination was notable for a nondysmorphic appear-
ing infant with poor head control, hyperexcitability, spontaneous
nystagmus, and intermittent episodes with ocular deviation sugges-
tive of seizures. Muscle tone and deep tendon reﬂexes appeared to
be normal. There was no hepatosplenomegaly and no cardiac mur-
mur. Ophthalmologic evaluation revealed spontaneous nystagmus,
diffuse optic nerve atrophy, and no reaction to light. Electroencepha-
lography demonstrated intermittent slow waves in the left parieto-
occipital region. Cranial magnetic resonance imaging showed
symmetrical areas of signal abnormalities in the basal ganglia and
bilateral frontal brain atrophy with subdural accumulation of cerebral
spinal ﬂuid. Laboratory investigations revealed a compensated meta-
bolic acidosis (base excess — 8.5 mmol/L) and a moderate lactate
acidemia (3.44 mmol/L [reference range: 1.06–1.89 mmol/L]). Analy-
sis of cerebrospinal ﬂuid showed normal cell count and protein with a
lactate of 3.7 mmol/L (reference range: 1.2–2.1 mmol/L) and pyru-
vate of 0.182 mmol/L. Amino acids in plasma and urine were normal.
Under the suspicion of an OXPHOS disorder, a muscle biopsy was per-
formed at the age of 6 months. Morphologic study of the muscle tis-
sue revealed no abnormalities. Over the following months, the girl
had progressive developmental delay, suffered from seizures, and
had poor feeding with failure to thrive. During a respiratory infection
with acute metabolic decompensation at the age of 8 months, the
patient died due to cardiorespiratory failure. NDUFS2 patients 2, 3,
4, and 5 have been described in detail before [26].
2.2. Fibroblast culturing
Fibroblasts were obtained following informed parental consent
and according to the relevant Institutional Review Boards from skin
biopsies of healthy subjects and complex I deﬁcient patients. Fibro-
blasts were cultured in HEPES (25 mM)-buffered M199 medium
(Invitrogen) supplemented with 10% (v/v) fetal calf serum, 5 mg/L
Tween 20, 100 IU/mL penicillin and 100 IU/mL streptomycin.
2.3. Biochemical and molecular genetic studies
The substrate oxidation rates, the ATP production rate from pyru-
vate, and the activities of mitochondrial complexes I–IV and citrate
synthase (CS) were performed in fresh muscle sample and culturedﬁbroblast as previously described [30–36]. Enzyme measurements
in muscle were performed in 600 g supernatant of crude homoge-
nates, whereas in the case of cultured ﬁbroblast mitochondrial-
enriched fractions were used. Statistical signiﬁcances were assessed
by Student's t-test. For the determination of the KM for CoQ1, complex
I activity was measured in the presence of a concentration series of
CoQ1 ranging from 2.5 to 200 μmol/L. The KM values were calculated
using an Eadie–Hofstee plot. Molecular genetic analysis of the coding
sequences of the NDUFS2 gene (Genbank accession # NM_004550)
was performed as follows. Total RNA was extracted from patient's
muscle tissue and reversely transcribed to cDNA. Following that,
NDUFS2 cDNA was ampliﬁed, and both strands were sequenced
using a method described before [26]. Furthermore, screening for
mtDNA rearrangement and common mtDNA point mutations were
performed using long-template PCR technique and double-stranded
sequence analysis, respectively.
2.4. Blue native PAGE (BN-PAGE), in-gel activity assays and Western
blotting
One-dimensional 10% SDS-PAGE and 5%–15% BN-PAGE was per-
formed as previously described [37]. Lanes were loaded with 40 μg
(SDS analysis) or 80 μg (BN analysis) of solubilized mitochondrial
protein. After electrophoresis, gels were processed further for in-gel
complex I activity assay, in-gel ﬂuorescence detection, immunoblot-
ting, or two-dimensional 10% SDS-PAGE as described before [38].
For blotting, proteins were transferred to a PROTAN nitrocellulose
membrane (Schleicher & Schuell). Complex I subunit antibodies
were ND1 (a gift from Anne Lombes, Paris, France), NDUFS2 (a gift
from Brian Robinson, Montreal, Canada), NDUFA9, and NDUFS3 (Invi-
trogen). Other antibodies used were raised against SDHA, Core II, and
COX4 (all Invitrogen). Secondary antibodies that were used are
peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Invitrogen).
Signal was generated with ECL Plus (Amersham Biosciences) and ex-
posed to X-ray ﬁlm (Kodak).
2.5. Baculoviral transduction
Recombinant baculoviruses containing the open reading frame of
NDUFS2 and NDUFS7 were made essentially as the previously de-
scribed NDUFA2 virus [23]. Patient ﬁbroblasts were grown to ~50%
conﬂuence in 175 cm2 tissue culture ﬂasks, and were transduced
with the appropriate baculovirus in a total volume of 25 mL M199
containing 2.3 mM sodium butyrate. After 24 h incubation at 37 °C,
the virus-containing medium was discarded and replaced with
normal growth medium containing sodium butyrate. Three days
after transduction, cells were harvested for gel electrophoresis and
spectrophotometric analysis of complex I and reference enzyme
activity measurements.
2.6. Membrane potential measurements
The membrane potential in patient 1 derived and control ﬁbro-
blast cell lines were determined by staining the cells with tetramethyl
rhodamine methyl ester (TMRM), which is sequestered in mitochon-
dria in a membrane potential dependent manner. Measurements
were performed according to previously published live-cell microscopy
methods [39].
2.7. Homology modeling
The structure of the human NDUFS2 protein is not known. We
used the respiratory complex 1 structure of Thermus thermophilus
(PDB ﬁle: 2FUG) as a template to model the corresponding human
subunits [40]. Human NDUFS2 and the corresponding bacterial subu-
nit share 46% sequence identity over 371 residues. The WHAT IF web
Table 1
Clinical, biochemical and genetic characteristics of ﬁve patients with mutations in the complex I NDUFS2 gene.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex F M F M M
Age of onset 2 weeks 6 months 2nd day 1st day 10 months
Age of death 8 months 24 months 18 months 4th day 36 months
Parental consanguinity + + + − +
Psychomotor retardation/regression + + + + +
Nystagmus + + + − +
Optic atrophy + + + − +
Hypertrophic cardiomyopathy − + + + −
Muscular hypotonia + + + + +
Extrapyramidal signs − − + − −
Epilepsy + − − − −
Apnea episodes − + − + +
Failure to thrive + − + NA
Recurrent vomiting + − − − +
Brain imaging Basal ganglia abnormalities,
cerebral atrophy
Basal ganglia
abnormalities
Generalized atrophy,
ventriculomegaly
ND Basal ganglia and
midbrain abnormalities
Blood lactate ↑ ↑ ↑ ↑ ↑
CSF lactate ↑ ↑ ND ND ↑
% CI in muscle 20 40 ND 24 69
% CI in ﬁbroblast 28 39 55 36 41
Mutation 1336G>A (D446N) 683G>A (R228Q) 683G>A (R228Q) 686C>A (P229Q) 1237T>C ( S413P)
%CI = percent complex I activity compared to the lowest control value; ND, not determined; NA, not applicable.
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building, energy minimization and analysis [42].3. Results
3.1. Clinical and biochemical characteristics of NDUFS2 patients
The clinical ﬁndings in the subject of this report, patient 1, in com-
parison to four other patients with mutations in the NDUFS2 gene, are
presented in Table 1. All patients show signs of Leigh syndrome, a
common feature of patients with mutations in nuclear encoded com-
plex I genes [16]. In addition, 3 out of the 5 NDUFS2 patients show hy-
pertrophic cardiomyopathy. The biochemical phenotype of patient 1
included a clearly reduced ATP production rate from pyruvate oxida-
tion to b30% of the lowest normal value (Table 2). Pyruvate oxidation
rates in the presence of malate as acetyl-CoA acceptor were more de-
creased than in the presence of carnitine, which is typical for OXPHOS
defects. A severe, isolated complex I deﬁciency was observed both in
muscle and cultured ﬁbroblast; the activity was reduced to 20% andTable 2
Biochemical studies in muscle and ﬁbroblast samples from NDUFS2 patient 1.
Substrate oxidations in muscle Result (control range)
[1-14C]pyruvate+malate 0.90 (3.61–7.48)a
[1-14C]pyruvate+carnitine 1.97 (2.84–8.24)a
[U-14C]malate+pyruvate 0.70 (4.68–9.62)a
ATP production from pyruvate 11.9 (42.1–81.2)b
Enzyme Musclec Fibroblastsc
Complex I 14 (70–251) 28 (100–310)
Complex II 406 (335–749) 672 (520–845)
Complex III 2544 (2200–6610) 1717 (1320–2610)
Complex IV 1420 (810–3120) 958 (680–1190)
Measurements of the substrate oxidation rates in a fresh muscle biopsy, and of
respiratory chain enzyme activities in a fresh muscle biopsy and in cultured skin
ﬁbroblasts. Control values are given between brackets and based on measurements
in samples from control individuals (n=25 for substrate oxidations, n=34 for
enzymes in muscle, and n=14 for ﬁbroblasts). Enzyme measurements in ﬁbroblasts
were performed in mitochondria-enriched fractions, whereas in the case of muscle tis-
sue 600 g supernatant.
a Activities in nmol/CO2/hour/unit citrate synthase.
b Activities in mU/unit citrate synthase.
c Activities in mU/unit citrate synthase.28% of lowest control values, respectively (Table 2). Similar to obser-
vations in several other complex I deﬁcient patients, the activity of
pyruvate dehydrogenase was slightly reduced in muscle and normal
in ﬁbroblasts (data not shown).
3.2. Identiﬁcation of NDUFS2 gene defect in patient 1
Sequence analysis of the NDUFS2 cDNA revealed a homozygous
c.1336G→A mutation in exon 14 of the NDUFS2 gene, which results
in replacement of an aspartic acid residue by an asparagine residue
at amino acid position 446 of the NDUFS2 protein (Fig. 1A). Additional
studies revealed no mutations in the mtDNA and in the nuclear
complex I genes NDUFS1, NDUFS4, NDUFS7, NDUFS8, and NDUFV1.
The mutated residue in the NDUFS2 protein is strongly conserved
among different species (Fig. 1B). Unfortunately, it was not possible
to obtain material from the parents for carrier testing.
3.3. Baculoviral complementation of NDUFS2 gene defect in patient 1
ﬁbroblasts
In order to further substantiate the pathogenicity of the
Asp446Asn mutation in the NDUFS2 gene in patient 1, a complemen-
tation experiment was performed in which patient derived ﬁbro-
blasts were transduced with a baculovirus-based hNDUFS2
expression construct. Results show that the complex I deﬁciency is
complemented by wild type NDUFS2 (Fig. 2A). A remarkable ﬁnding
was that complex I analysis by both BN-PAGE and by in-gel activity
measurements showed normal complex I levels in ﬁbroblasts
(Fig. 2B). For the other NDUFS2 deﬁcient cell lines, the in gel complex
I activities correlated with the spectrophotometric complex I
activities (data not shown). These observations indicate that the
Asp446Asn, in contrast to the other mutations studied here, results
in a reduced enzyme activity and not a reduced enzyme amount,
and therefore should be considered a catalytic mutation.
3.4. NDUFS2 protein levels and complex I assembly
The expression of the NDUFS2 subunit correlated with the amount
of holo-complex I, as ﬁbroblasts of patient 1 expressed NDUFS2 pro-
tein at a near normal level (Fig. 3), whereas NDUFS2 was not detect-
able in ﬁbroblasts of patients 4 and 5. Analysis of complex I assembly
in the ﬁbroblasts of these three NDUFS2 patients showed no
Fig. 1. Molecular genetic analysis of the NDUFS2 cDNA from patient 1. (A) Results of the sequence analysis of a healthy control and NDUFS2 patient 1. Protein and cDNA sequence
numbering is indicated. The arrow indicates the mutated nucleotide. (B) Evolutionary conservation of amino acid residue 446 (arrow) of the human NDUFS2 protein.
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ing difference was that ﬁbroblasts of patients 1 showed the presence
of a large subcomplex, which has previously been suggested to be a
degradation product of complex I [43], suggesting that complex I in
patient 1 is less stable than in controls (Fig. 4). Whether patients 4
and 5 also contain this degradation product was difﬁcult to judge, as
the total amount of complex I in these patient cell lines was very low.
3.5. Three dimensional modeling of NDUFS2 mutations
Modeling of the NDUFS2 mutations in a 3-dimensional model of
the dehydrogenase domain of complex I revealed that the catalytic
NDUFS2 Asp446Asn mutation in patient 1 is located near the hydro-
phobic, membrane-associated subunits and near the site where
CoQ10 is thought to interact with complex I (Fig. 4). CoQ10 has been
proposed to interact at the interface of NDUFS2 and NDUFS1, al-
though the possibility of additional sites of interaction with CoQ10
has not been completely excluded yet [44].
3.6. The effect of the Asp446Asn mutation in NDUFS2 on CoQ binding,
rotenone sensitivity and membrane potential
We tested whether the Asp446Asn NDUFS2 mutation affects in-
teraction with CoQ by determining the KM for CoQ1, which is used
as an electron acceptor in our complex I assay, and for decylubiqui-
none, another coenzyme Q10 analog. Results show that the KM for
both substrates is similar to those measured for other complex Ipatients and healthy controls (Table 3), and is also in the range of pre-
viously published values [45]. By comparing the residual NADH:CoQ
oxidoreductase in the presence of rotenone in different complex I de-
ﬁcient and control cell lines, we found no evidence for a reduced ro-
tenone sensitivity due to the NDUFS2 mutation of complex I, which
indicates that the mutation does not interfere with rotenone binding
of complex I. The effect of the Asp446Asn mutation and reduced com-
plex I activity on the membrane potential was examined by staining
the ﬁbroblasts of patient 1 with tetramethyl rhodamine methyl
ester (TMRM), which is sequestered in mitochondria in a membrane
potential dependent manner [39]. Previously, we have shown that
membrane potential values in different complex I deﬁcient ﬁbroblast
cell lines vary between clearly reduced to near normal, with TMRM
signals between 87% and 98% of that measured in control cells [16].
Analysis of the membrane potential in the ﬁbroblasts of patient 1
shows a TMRM signal that is 99% of that in control cell lines, indicating
that the Asp446Asn mutation does not result in a reduced membrane
potential.
4. Discussion
4.1. A catalytic defect in complex I
In this report, we compared the clinical and biochemical features
of 5 patients with mutations in the complex I NDUFS2 gene. The
most striking clinical features in this group of patients are Leigh
syndrome (5/5 patients) and hypertrophic cardiomyopathy (3/5
Fig. 2. Complementation of complex I activity in ﬁbroblasts of NDUFS2 patient 1. (A)
Results of spectrophotometric analysis of complex I activity (average of four measure-
ments). Cells were incubated in the absence or presence of NDUFS2 or control virus. As
control experiments, identical incubations were performed on a control cell line and on
a cell line carrying a Val122Met mutation in NDUFS7. The dashed lines indicate the ac-
tivity per ﬁbroblast cell line in the absence of virus. Complex I activities measured in
the NDUFS2 patient cell line after incubation with the NDUFS2 virus were signiﬁcantly
different from those measured after incubations with mock (p=0.001) and control
virus (p=0.02). Complex I activities measured in the other two cell lines with or with-
out incubations with viruses were not statistically different (p>0.05). (B) Results of
BN-PAGE/Western blot and in-gel activity analysis of complex I. Cells were incubated
in the absence or presence of NDUFS2, VSV-tagged NDUFS2 or control virus. Results of
the complex I in-gel activities are shown in the top panel. The middle panel shows the
amounts of complex I as determined by Western blotting of blue native gels using an
antibody against the NDUFA9 subunit of complex I. As a loading control, complex II
was stained using an antibody against the FP subunit (lower panel). As control exper-
iments, identical incubations were performed on a control cell line and on a cell line
carrying a mutation in NDUFS7.
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frequently in NDUFS2 defects than in other complex I defects, it
should be noted that in a recent study cardiomyopathy was not ob-
served in six NDUFS2 patients with Leigh syndrome [46]. We identi-
ﬁed a catalytic complex I defect in one of our NDUFS2 patients. The
pathogenicity of the catalytic NDUFS2 defect in this patient is sup-
ported by the following observations: (1) spectrophotometric com-
plex I enzyme activities are strongly reduced, (2) the clinical
phenotype resembles that of other NDUFS2 patients, (3) the mutation
is located in a highly conserved region of the NDUFS2 gene, (4) the
mutation is not present in 200 control alleles from subjects with the
same ethnic background, and (5) transduction of wild type NDUFS2
leads to a speciﬁc increase of complex I activity in ﬁbroblasts of this
patient. The conclusion that this mutation results in a catalytic defect
is based on the ﬁndings that the activity of complex I is severely re-
duced, while the amounts of complex I are normal. This feature was
not observed in ﬁbroblasts from other patients with NDUFS2 muta-
tions, nor has it been observed in any other ﬁbroblast cell line from
patients with mutations in nuclear complex I genes [16]. To our
knowledge, this is the ﬁrst time a catalytic defect in a nuclear encodedcomplex I subunit has been demonstrated in patient cells. Previous
studies on catalytic defects in complex I have been performed in a
laboratory model organism, Yarrowia lipolytica, in which the patho-
genic mutation was introduced [45]. Modeling of the mutation in a
3-dimensional model of complex I revealed that the mutation is locat-
ed at the periphery of the NDUFS2 protein close to the membrane
subunits of complex I and on the opposite side of the region in the
NDUFS2 subunit where the other pathogenic mutations have been
found. This correlates with the different biochemical features of the
NDUFS2 patients studied here. Interestingly, Tuppen et al. [46] re-
cently described the NDUFS2 mutation Met443Lys, which is located
very close to the Asp446Asn mutation described here. Because the
Met443Lys mutation was found compound heterozygous with the
Met292Thr mutation, it is not possible to deduce from the data pre-
sented by Tuppen et al. if the Met443Lys mutation could be a catalytic
mutation. However, it is noteworthy that both in-gel complex I activ-
ity and holo-complex I protein levels were relatively high [46], similar
to the observations presented here for the homozygous Asp446Asn
mutation.
4.2. Effect of Asp446Asn mutation on the interaction of complex I with
CoQ
The exact mechanism of the catalytic defect remains to be estab-
lished. The interaction between CoQ and complex I appears not to
be affected by the mutation, as the KM for CoQ1 was normal in all
NDUFS2 patients, nor does the residue appears to reside near the ter-
minal Fe–S cluster N2. Possibly, the mutation interferes with the elec-
tron transport between the ﬁnal Fe–S cluster N2 and CoQ10, since the
mutation is located near the site where CoQ10 interacts with complex
I. Although CoQ1 was used for this experiment instead of CoQ10, it is
the same electron acceptor that was used in the spectrophotometric
assay in which the complex I deﬁciency was observed.
4.3. Effect of Asp446Asn mutation on proton pumping by complex I
Another possibility is that the aspartic acid residue at position 446
plays a role in the coupling of electron transfer and proton pumping,
and in the putative functional-conformational changes that complex I
has been proposed to undergo [47]. Efremov et al. propose a mecha-
nism in which proton translocation is coupled with conformational
changes at the interface between the hydrophobic and hydrophilic
domains [48]. Strong contacts between the subunits of the complex
are required in order to transfer the conformational change trough
the complex. It was suggested that subunit NDUFS2 mediates the ma-
jority of the interactions with subunit Nqo8 and Nqo7/10/11. Residue
Asp446might be one of the residues that interacts with those charged
residues that are strongly conserved in the cytoplasmic loops of sub-
unit Nq08. The observation that the membrane potential measured in
the Asp446Asn ﬁbroblasts is similar to that in controls seems to be in
conﬂict with the hypothesis of a disturbed coupling between electron
transfer and proton pumping. However, the fact that the membrane
potential in different complex I deﬁcient cell lines vary from clearly
reduced to normal, without a clear correlation with the type of genet-
ic defect, suggests that complex I is not the only factor inﬂuencing the
steady state membrane potential in these cells [16]. In conclusion,
additional studies are required to elucidate the possible role of the
Asp446 residue of the NDUFS2 protein in electron transfer and proton
pumping.
4.4. Turn-over of complex I
In 2D BN-PAGE experiments, a large complex I degradation prod-
uct was seen in ﬁbroblasts of patient 1, suggesting that complex I is
less stable in this patient than in healthy controls. Whether a similar
degradation product is present in the other NDUFS2 defects could not
Fig. 3. Analysis of complex I holo-complex and subassemblies, and NDUFS2 protein levels in ﬁbroblasts from three NDUFS2 patients. (A) Blue Native PAGE results showing a near
normal complex I in-gel activity (IGA) and amount (staining with anti-NDUFA9 antibody). The amounts of complexes II, III, and IV were similar in all four cell lines. (B) SDS PAGE
showing that NDUFS2 levels in patient 1 (P1) are considerably higher than in patients 4 and 5, but not as high as in control cells. Equal loading of the gel was conﬁrmed by staining
with the 70 kDa FP (SDHA) subunit of complex II. (C) Two-dimensional PAGE showing the presence of a degradation product of complex I [43] in patient 1, indicated by an arrow.
No striking differences in the ratios of the different subassemblies between different patient cell lines and control cell line could be observed.
173L.H. Ngu et al. / Biochimica et Biophysica Acta 1822 (2012) 168–175be established, as these patients had very low residual complex I
amounts. The presence of the degradation product in combination
with normal amounts of holo-complex I is suggestive for an increased
turn-over rate of complex I in this patient. We have speculated before
that the reduced amount of complex I seen in most complex I patients
could be due increased breakdown caused by the elevated reactiveFig. 4. Three dimensional model of the NDUFS2 subunit in the NADH-dehydrogenase modu
dicated in the model of the NADH-dehydrogenase module (left ﬁgure) [44,51]. The location
4 (Pro229Gln), and 5 (Ser413Pro) is indicated in red (right ﬁgure). It shows that the cataly
pocket to which CoQ10 binds, which is at the opposite side of the protein compared to theoxygen species production seen in many patient-derived cell lines
[16], including the Asp446Asn cell line (cell line #7276 in Ref. [49]).
However, the observations in the Asp446Asn NDUFS2 patient demon-
strate that this does not necessarily has to be the case, as reactive ox-
ygen species production is elevated to a similar extent as in other
NDUFS2 patients and yet does not result in a decrease of fullyle of complex I. The NDUFS2 subunit is shown in blue. The CoQ10 binding pocket is in-
of the mutated amino acids in NDUFS2 in patients 1 (Asp446Asn), 2 and 3 (Arg228Gln),
tic mutation in patient 1 is located near the membrane subunits of complex I and the
region where other NDUFS2 mutations studied in this report are located.
Table 3
KM for CoQ1 and decylubiquinone (DQ) for NDUFS2 patients 1 and 4, a Val122Met
NDUFS7 patient, and two healthy controls.
Subject KM (CoQ1)a KM (DQ)a
Healthy control 1 55 μM 10.2 μM
Healthy control 2 38 μM 10.2 μM
NDUFS7 patient 91 μM 6.4 μM
NDUFS2 patient 1 55 μM 6.3 μM
NDUFS2 patient 4 61 μM 6.3 μM
a The KM values were derived from Eadie–Hofstee plots of the complex I activity
measured in the presence of concentration series of CoQ1 and DQ.
174 L.H. Ngu et al. / Biochimica et Biophysica Acta 1822 (2012) 168–175assembled complex I. Also other cell biological features, such as Ca2+
homeostasis parameters and mitochondrial morphology, are not
strikingly different in NDUFS2 patient 1 compared to other complex
I patients [49,50]. Further experiments are required to elucidate the
precise molecular mechanism behind the effect of different complex
I mutations on its stability and turn-over.
5. Conclusions
A homozygous Asp446Asn mutation in NDUFS2 results in a se-
verely reduced complex I activity, while the amount of complex I is
normal. This indicates that the mutation results in a catalytic defect
of complex I. To our knowledge, this is the ﬁrst time such a defect in
a nuclear encoded subunit has been demonstrated in patient cells.
Although the mutation resides near the CoQ binding pocket, it does
not result in an altered KM for coenzyme Q analogs. On the basis of
these ﬁndings, we propose that the mutation interferes with
coenzyme Q reduction or disturbs the coupling between coenzyme Q
conversion and the proton pumping machinery of complex I.
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